PharmaCyte Biotech (OTCMKTS:PMCBD) Trading Up 0.4%
PharmaCyte Biotech (OTCMKTS:PMCBD) Trading Up 0.4%
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Rating) shares traded up 0.4% on Tuesday . The company traded as high as $2.88 and last traded at $2.84. 33,197 shares traded hands during mid-day trading, an increase of 276% from the average session volume of 8,831 shares. The stock had previously closed at $2.83.
藥典生物科技股份有限公司 (OTCMKTS: PMCBD — 獲得評級) 股份週二上漲了 0.4%。該公司的交易價格高達 2.88 美元，最後交易價為 2.84 美元。33,197 股在中間交易手，較 8,831 股平均交易量增加 276%。該股票之前已收盤 2.83 美元。
PharmaCyte Biotech Stock Down 0.4 %
藥典生物科技庫存下跌 0.4%
The company's fifty day moving average price is $2.93 and its two-hundred day moving average price is $2.87.
該公司的五十天移動平均價為 2.93 美元，其 200 天移動平均價格為 2.87 美元。
PharmaCyte Biotech Company Profile
藥典生物科技公司簡介
(Get Rating)
(取得評分)
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
PharhySyte 生物科技股份有限公司是一家臨床階段的生物技術公司，致力於癌症和糖尿病治療的開發和商業化。它專注於一種專有的基於纖維素的活細胞封裝技術，稱為 Cell-in-a-Box，該技術將用作開發無法手術的胰腺癌和其他實體癌性腫瘤以及糖尿病治療的平台。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on PharmaCyte Biotech (PMCBD)
- The Squeeze Is On For EVGo, Rally To Follow
- Is The Bottom In For RH, Or Is This Just A Stopping Point?
- Dividend King H.B. Fuller Signals Slowing In 2023
- Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
- 3 Companies That Just Started Paying Dividends
- 獲取有關藥物學生物技術研究報告的免費副本
- eVGo 的擠壓正在進行，集會跟隨
- 是 RH 的底部，還是這只是一個停止點？
- 股息國王 H.B 富勒信號在 2023 年放緩
- SoFi 技術在銀行危機中是否可以購買？
- 3 家剛開始支付股息的公司
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
接收有關藥劑生物技術日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Pharyyte 生物技術及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。
